Bipolar Disorder
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (18)
Approved therapies currently available
Competitive Landscape
38 companies ranked by most advanced pipeline stage
+8 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 7,531 patients across 50 trials
An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
Gao NARASD Lithium Study
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
Iloperidone in Mixed States of Bipolar Disorder
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness
Allopurinol Add-on Treatment for Refractory Mania
Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia
Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study
Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes
Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder
Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
Ropinirole in the Treatment of Bipolar Depression
A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
Short Term Rescue Study of Olanzapine
Aripiprazole for the Treatment of Refractory Anxiety
Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
Abilify as an Adjunctive Treatment for Refractory Depression
Abilify Therapy for Reducing Comorbid Substance Abuse
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
Valproic Acid Sodium Salt in Bipolar Disorder
Trial of Aripiprazole in the Treatment of CD in Adolescents
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
12- Week Open Label Treatment of Refractory Bipolar Depression
Aripiprazole in Late Life Bipolar Disorder
The Effects of Aripiprazole on Patients With Metabolic Syndrome
Depakote ER Therapy for Mania Comorbid With Substance Abuse
VALID : VAlproate Versus LIthium in Bipolar Disorders
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder
Bipolar Study in Adults at Least 18 Years of Age
Depakote-ER for Depressive and Bipolar Depression
Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.
Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
Related Jobs in Neurology
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Associate Director, Operational Procurement
Sales Support Representative (Temp-to-Hire)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.